Buy Retatrutide in New York: Triple-Action Weight Loss
New York residents can access the most powerful weight loss medication through TRIMI telehealth.
Retatrutide represents the cutting edge of weight loss pharmacology. As the first triple-action agonist (GLP-1 + GIP + glucagon), it delivers up to 24% body weight loss -- surpassing both semaglutide and tirzepatide. New York residents can access compounded retatrutide through TRIMI's licensed telehealth platform.
Triple-Action Mechanism
GLP-1
Appetite suppression and slowed gastric emptying.
GIP
Enhanced insulin sensitivity and fat metabolism.
Glucagon
Increased energy expenditure and fat burning.
Medication Comparison
| Medication | Receptors | Weight Loss |
|---|---|---|
| Semaglutide | GLP-1 | 15-17% |
| Tirzepatide | GLP-1 + GIP | 20-22% |
| Retatrutide | GLP-1 + GIP + Glucagon | Up to 24% |
New York Access
NY Availability
- • Telehealth: Virtual consultations statewide
- • Shipping: 3-7 day delivery to all NY addresses
- • NYC: All five boroughs covered
- • Upstate: Full coverage Albany to Buffalo
Ideal Candidates
- Patients who plateaued on semaglutide or tirzepatide
- BMI 30+ (or 27+ with comorbidities)
- Those seeking maximum weight loss potential
- Patients with significant metabolic syndrome
Getting Started
- Online assessment of health history and goals
- Virtual consultation with NY-licensed provider
- Custom dosing plan tailored to your needs
- Home delivery to your New York address
Medical Disclaimer
This article is for informational purposes only. Retatrutide is investigational and available through compounding pharmacies. Requires provider evaluation. Side effects include nausea, vomiting, diarrhea, and decreased appetite.
Explore Retatrutide in New York
The most advanced weight loss treatment. Connect with a NY-licensed provider today.
Explore Treatment OptionsMore on state guides
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).